1.Clinical significance of detecting minimal residual disease in acute leukemia
Lidong ZHAO ; Yin WANG ; Jianping MAO ; Jin YANG ; Shaolin ZHAO ; Ze CHEN ; Huijie LIU ; Dongmei YAN ; Zhimei CAI ; Tao JIA
Journal of Leukemia & Lymphoma 2009;18(2):102-103,106
Objective To investigate the clinical significance of flow cytometry (FCM) assay in following up of the minimal residual disease (MRD) used for predicting relapse and guiding chemotherapy. Methods The clinical data of 43 acute leukemia patients diagnosed by MIC were collected in our hospital from 2005 July to 2008 June.Bone marrow aspirates were collected from 43 patients with newly diagnosed acute leukemia after induction therapy and during constimulation therapy. The cells with leukemia associated with immunophenotype were investigated using FCM, as immunologic target of MRD. Results MRD were detected earlier in predicting the relapse than those of the traditional bone marrow cells morphology assay by an average of 4-6 months. The results of the MRD following up: MRD was negative at CR in 26 cases, 6 cases relapse, 20 cases of them were kept negative during following up. MRD was positive in 17 cases at CR, 9 cases of them were relapse. 4 cases after intensified chemotherapy the MRD became negative and kept egative for more than one year. The MRD of the 43 cases at CR were divided into 3 groups, MRD less than 1×10-4 group (A group) MRD between 5×10-3 and 1×10-4 group (B group) and MRD above 5×10-3 group(C group). By chi square test. There was no statistical significance between A group and B group, but there was tatistical significance between B group and C group (P=0.02). Conclusion The application of FCM in detecting MRD has important clinical significance in predicting relapse and guiding chemotherapy.
2.Follow-up study on refractory schizophrenia with brain stereotaxis therapy.
Yi CAI ; Weiping KUANG ; Tiansheng GUO ; Hongxing HUANG ; Zhimei WU ; Bin ZHOU ; Yong ZHU ; Xiaofeng CHEN ; Bo LI ; Hongxian CHEN
Journal of Central South University(Medical Sciences) 2011;36(9):876-880
OBJECTIVE:
To determine the long-term effect and security of refractory schizophrenia with brain stereotaxis multi-target therapy technique.
METHODS:
A total of 87 patients with refractory schizophrenia were treated with brain stereotaxis multi-target therapy and were followed up over 2 years. The scores of Clinical Global Impression, Brief Psychiatric Rating Scale, Positive and Negative Symptom Scale, Wechsler Adult Intelligence Scale, Wechsler Memory Scale, Actives of Daily Living, and Social Disability Screening Schedule were compared before and after the operation.
RESULTS:
Of the 87 patients, 40 obviously improved, 24 improved, 12 improved little, 7 did not change. None grew worse, 1 died, and 3 shed. There was a significant difference in the scales before and after the operation (P<0.01). No severe complications and sequelae occurred.
CONCLUSION
Stereotaxic multi-target therapy is effective and safe for refractory schizophrenia. After the operation, drug therapy should be maintained and recovery of social function is helpful.
Adult
;
Brain
;
surgery
;
Brief Psychiatric Rating Scale
;
Female
;
Follow-Up Studies
;
Humans
;
Male
;
Middle Aged
;
Psychiatric Status Rating Scales
;
Schizophrenia
;
surgery
;
Stereotaxic Techniques
;
Young Adult
3.Geritinib in the targeted therapy of acute myeloid leukemia with FLT3 mutation: report of 5 cases and review of literature
Weiling LIANG ; Jihao ZHOU ; Yun CAI ; Lixin WANG ; Guoqiang LI ; Bingbing WEN ; Weiqiang ZHAO ; Gong ZHONG ; Jun WANG ; Jianliang CHEN ; Xiaolin PEI ; Li ZHOU ; Zhimei ZHU ; Hua YANG
Journal of Leukemia & Lymphoma 2022;31(11):669-674
Objective:To investigate the efficacy and safety of geritinib in the treatment of acute myeloid leukemia (AML) with FLT3 mutation.Methods:The clinical data of 5 AML patients with FLT3 mutation who were diagnosed in the University of Hong Kong-Shenzhen Hospital, Shenzhen People's Hospital, Shenzhen Second People's Hospital, Shenzhen University General Hospital from March 2020 to April 2021 were retrospectively analyzed. Relapsed patients concurrently received two- or three-drug chemotherapy combined with geritinib. Blood routine was checked once a week; liver function and renal function were checked once every 2 weeks during treatment. Bone marrow puncture was performed once every 1 to 3 months to monitor the bone marrow morphology, minimal residual disease (MRD) and FLT3 mutation expression levels. The efficacy, side effects, overall survival of these patients were analyzed after treatment with geritinib.Results:The white blood cell was increased in all the 5 patients at the initial diagnosis. FLT3 mutations analysis showed FLT3-internal tandem duplication (ITD) (3 cases) and FLT-3 tyrosine-kinase domain (TKD) (2 cases). Among 5 patients, 1 patient was relapse-free with maintenance therapy of oral geritinib after hematological stem cell transplantation (HSCT) for 60 days; among other 4 relapsed and refractory patients, 1 female patient after pregnancy relapsed after transplantation and then achieved complete remission followed by the maintenance therapy with geritinib after oral geritinib, 1 16-year-old patient achieved treatment outcome close to the complete remission after treatment with geritinib, 1 patient achieved complete remission after treatment with geritinib, and then underwent haplo-HSCT followed by the maintenance therapy with geritinib and the other 1 relapsed patient achieved complete remission after treatment with geritinib. After transplantation, 3 patients receiving maintenance treatment of geritinib did not relapse. The main side effects included anemia, decreased neutrophil count, rash, and increased aminotransferase. The median follow-up time of 5 patients was 15 months (6-20 months). All 5 cases survived until the last follow-up in November 2021 and 4 patients were disease-free.Conclusions:Relapsed and refractory AML patients with FLT3 mutation can achieve complete remission after treatment with geritinib and get a chance for transplantation. Geritinib may reduce the risk of recurrence after transplantation and improve survival rate. No serious side effects occur in geritinib treatment.
4. MRI-visible and pH-sensitive nanomicelles for targeting delivery of sorafenib to hepatocellular carcinoma
Mingyue CAI ; Ge LYV ; Qin YANG ; Liteng LIN ; Jingjun HUANG ; Zhimei ZHOU ; Yong HUANG ; Hui LIAN ; Mingji HE ; Kangshun ZHU
Chinese Journal of Radiology 2019;53(11):1005-1011
Objective:
To synthesize a folic acid (FA)-modified pH-sensitive nanomicelle containing sorafenib (SF) and superparamagnetic iron oxide (SPIO), and to access its visibility in MRI and anti-cancer efficacy on hepatocellular carcinoma (HCC)
5.Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
Jingjun HUANG ; Mingyue CAI ; Wensou HUANG ; Yongjian GUO ; Jingwen ZHOU ; Licong LIANG ; Liteng LIN ; Zhimei ZHOU ; Hui LIAN ; Mingji HE ; Kangshun ZHU
Chinese Medical Journal 2021;135(1):113-115